Introduction
The immunosuppressive xenobiotic drug mycophenolate mofetil (MMF) is currently used to prevent organ transplant rejections (Mele and Halloran, 2000; Ciancio et al., 2005; Danovitch, 2005; Shapiro et al., 2005) . MMF efficacy has been mostly attributed to its inhibitory activity on lymphocyte functions, that make MMF an effective immunosuppressive drug. Mechanistically, it has been shown that mycophenolic acid (MPA), the bioactive compound of MMF, inhibits the activity of inosine monophosphate deshydrogenase, a rate-limiting enzyme for de novo synthesis of guanosine nucleotides (Allison and Eugui, 2000) . By depleting the intracellular concentration of guanosine nucleotides, MPA acts as a powerful inhibitor of lymphocyte proliferation. While the principal therapeutic indication of MMF is transplantation, clinical and experimental observations suggest that it may also represent a plausible option for the treatment of immune diseases such as systemic sclerosis (SSc) (Stratton et al., 2001; Liossis et al., 2006) or graft-versus-host disease (GVHD) (Arai and Vogelsang, 2000; Zeiser et al., 2004) . For example, in rodent models, oral administration of MMF alone or in combination with cyclosporin A inhibits the sclerotic manifestations of GVHD (Allison and Eugui, 2000) . In humans, successful treatment of high risk chronic GVHD with MMF has also been reported on a limited number of patients (Allison and Eugui, 2000; Kim et al., 2004; Krejci et al., 2005; Lopez et al., 2005) .
SSc and GVHD are heterogeneous immune diseases characterized by predominant T cell activation, production of autoantibodies, and cytokine release. These events contribute to fibroblast activation and lead to increased deposition of collagen at various organ sites, ultimately producing localized fibrosis, lastly leading to organ failure and death (Derk and Jimenez, 2003; Ruzek et al., 2004; Abraham and Varga, 2005; Hess, 2006; Verrecchia et al., 2006) . The development of fibrosis also involves a series of distinct, yet complementary, pathophysiological events that include attraction of blood-born cells (e.g., leukocytes, platelets, activated lymphocytes), local alteration of the microvasculature (interrupting non-thrombogenic, permeability-regulating, and cell-adhesive functions of the microcirculation), and activation of resident mesenchymal cells (e.g. fibroblasts, JPET#117051 5 endothelial cells, pericytes) leading to excessive collagen deposition and ECM contraction (Uitto and Kouba, 2000; Verrecchia and Mauviel, 2002a; Verrecchia and Mauviel, 2002b; Leask and Abraham, 2004) . Tissue fibrosis is generally considered to arise due to a failure of the normal wound healing response to terminate (Eckes et al., 2000; Gabbiani, 2003) . During this process, fibroblasts proliferate, migrate into the wound and synthesize elevated levels of ECM proteins, particularly fibrillar collagens. Alternatively, reduced matrix metalloproteinase (MMP) expression, and subsequent inhibition of collagen degradation may also contribute to the fibrotic process (Uitto and Kouba, 2000) . A specialized form of fibroblasts present in wounds, called myofibroblasts, expresses high levels of α-smooth muscle actin (α-SMA) and consequently contracts the ECM, thereby allowing wound closure (Gabbiani, 2003) . Myofibroblasts are present in abundance within fibrotic lesions and notably contribute to excessive ECM deposition and scaring (Gabbiani, 2003) .
The aim of this work was to investigate whether MMF exerts direct effects on fibroblast functions.
We demonstrate that MMF inhibits collagen gene expression, ECM contraction, and fibroblast migration suggesting that it may exert direct antifibrotic activities independent from its role as an immunosuppressive drug.
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Methods
Cell cultures. Human lung fibroblasts (WI-26) were grown in Dulbecco's modified Eagle's medium supplemented with 10% heat-inactivated fetal calf serum (FCS), 2 mM glutamine, and antibiotics (100 units/ml penicillin, 50 mg/ml streptomycin-G and 0.25 mg/ml Fungizone™) in 5% CO 2 at 37°C. Mycophenolate mofetil was obtained from Roche Pharmaceuticals (Nutley, NJ).
Cell viability assesment. Subconfluent WI-26 fibroblasts were cultured in 96 well cell culture cluster and treated with various concentrations of MMF for 12h, 24h and 48h in the presence of 1% FCS. Cell viability was assessed with an MTT assay, according to the manufacturer's protocol (Promega, Madison, WI).
Collagen matrix contraction. Fibroblasts were harvested from monolayer cultures with 0.25% trypsin and 1 mM EDTA. Trypsin was subsequently neutralized with fetal calf serum-containing medium. Collagen lattices in 60-mm dishes were prepared with 7 ml of a mixture containing 3.10 5 fibroblasts and 1 mg/ml native type I collagen (Biocoat™; BD Biosciences) in medium supplemented with 1% FCS. When needed, MMF was added to the mixture before polymerization of the collagen matrix. Polymerization of collagen matrices required 60 min at 37 °C. To initiate lattice contraction, freshly polymerized matrices were released from the underlying culture dish with a few gentle taps on the dish (Javelaud et al., 2003) .
Scratch wound closure assays. Confluent cell monolayers were wounded by mechanical scraping with a pipette tip. Wound width was assessed at the time of scrapping to ensure that all wounds were the same width at the start of the experiments (see corresponding figures). Cell culture medium was then replaced with fresh medium, with or without MMF at various concentrations, and wound closure was recorded photographically over time using phase-contrast microscopy (Javelaud et al., 2003) .
Transwell
TM Motility Assays. Single cell suspensions were seeded onto the upper surface of the filters in medium containing 10% fetal calf serum and allowed to migrate through the membrane.
After a 24h or 48h incubation period, cells on the upper surface of the filter were wiped off with a pRSV-β-galactosidase was cotransfected in every experiment to monitor transfection efficiencies.
CAT activity was measured using ( 14 C)chloramphenicol as substrate, followed by thin-layer chromatography, as described previously (Verrecchia et al., 2002) . Quantitations were made with a PhosphorImager (Amersham Biosciences, Uppsala, Sweden).
Plasmid constructs. -3500COL1A2/CAT (gift from Francesco Ramirez, Mt Sinai School of
Medicine, New York, NY), and -2300COL1A1/CAT (gift from John Varga, Northwestern University Feinberg School of Medicine, Chicago, IL) have been previously decribed (Boast et al., 1990; Chen et al., 1998) .
Western blot analyses.
Total cell extracts (30 µg) in Laemmli buffer (62.5 mM Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, 0.5 mM phenylmethylsulfonyl fluoride) were denatured by heating at 95°C
for 3 min before resolution by SDS-polyacrylamide gel electrophoresis. After electrophoresis, Quantative determination of MMP-1 production. The MMP-1 production in cell supernates was determined using the Quantikine Human pro-MMP-1 Immunoassay kit from R&D Systems (Minneapolis, MN) according to the manufacturer's instructions.
Results
MMF inhibits type I collagen gene expression.
To determine whether MMF had a direct effect on collagen production by fibroblasts, WI-26 human fibroblast cultures were incubated with various concentrations of MMF, and type I collagen production was estimated by Western Blot analysis. As shown in Figure 1 , total type I collagen production was reduced by MMF in a time-and dose-dependent manner. A decrease of approximately 60% and 80% with a concentration of 10 µM, and a decrease of 50% and 72% with a concentration of 1 µM were respectively observed after 48h and 72h of treatment. Even the lowest concentration of MMF, 0.1 µM, had a significant inhibitory activity after 48h of incubation, suppressing collagen production by as much as 20%. No toxicity of MMF and no change in cell proliferation, as assessed by MTT test, was observed during the course of these experiments, at any of the concentrations tested (not shown).
To determine whether the reduction of type I collagen production in response to MMF occurred via modulation of the corresponding genes, COL1A1, and COL1A2 mRNA steady-state levels were estimated by quantitative RT-PCR. As shown in We first wanted to determine whether MMF had direct effect on MMP-1 synthesis. To adress this point, MMP-1 protein production was measured using MMP-1 immunoassay approach. As shown in Figure 4A , MMF treatment of WI-26 fibroblasts led to increase in MMP-1 protein production, up to 2,6-fold and 4,6 fold respectively after 48h and 72h at the concentration of 10 µM. We next determined whether MMF modulates MMP-1 and/or TIMP-1 gene expression. To address this point, the effects of MMF on MMP-1 and TIMP-1 mRNA steady-state levels were studied by quantitative RT-PCR. MMF treatment of WI-26 fibroblasts led to a time dependent increase in MMP-1 mRNA levels, up to 5,3-fold after 72h at the concentration of 10 µM (Fig. 4B) . On the other hand, TIMP-1 gene expression remained unaltered over the same incubation period (data not shown).
MMF reduces fibroblast capacity to contract free-floating collagen lattices.
We next wanted to determine whether MMF alters ECM contraction by fibroblasts, a phenomenon that mechanistically involves both ECM remodeling and cell motility (Grinnell, 1994) . To this end, WI-26 were seeded in free-floating, mechanically unloaded, collagen gels, and incubated in the presence or absence of MMF. The kinetics of collagen lattice contraction was then recorded over a 5-day period. Results shown in Figure 5 indicate that MMF had a potent dose-dependent inhibitory effect on collagen lattice contraction by WI-26 fibroblasts. At day 5, MMF treatment at concentrations ranging from 0,1 µM to 10 µM resulted in significant greater lattice diameter relative to control, indicating inhibition of fibroblast contractile activity: up to 50% increase in lattice diameter relative to control was observed at 5 days following treatment with 10 µM MMF. In addition, MPA (10 µM) mimics the effect of MMF (data not shown).
MMF reduces α-smooth muscle actin gene expression
α-SMA expression is the hallmark of the myofibroblast phenotype, and is thought to contribute to their contractile activity (Skalli et al., 1986; Desmouliere et al., 2005) . To determine whether MMF had a direct effect on α-SMA expression, WI-26 fibroblast cultures were incubated with MMF for various time periods, following which α-SMA production was measured by Western Blot analysis.
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As shown in Figure 6A , α-SMA production was reduced by MMF in a time dependent manner. A decrease of 22%, 30% and 69% with a MMF concentration of 10 µM was respectively observed after 2, 3, and 5 days of treatment. To determine whether the reduction of α-SMA production by MMF occurred via modulation of the corresponding gene, we measured α-SMA mRNA steady-state levels following MMF treatment by quantitative RT-PCR. As shown in Figure 6B , MMF at a concentration of 10 µM decreased α-SMA mRNA levels in a time-dependent manner. A decrease of 34%, 60% and 83% with a MMF concentration of 10 µM was respectively observed after 2 days, 3 days and 5 days of treatment.
MMF inhibits fibroblast motility
The effects of MMF on WI-26 fibroblasts migration were assessed firstly in a scrape wounding assay. As shown in Figure 7A , photomicrographs taken 3h, 8h and 24h after wounding show delayed wound closure by WI-26 fibroblast cultures treated with MMF at concentrations ranging from 0,1 µM to 10 µM compared with untreated control cultures. Quantitation of the wound closure over time revealed a significant inhibitory effect of MMF on fibroblast motility (Fig. 7B) , even the lowest concentration of MMF, 0.1 µM, after 24h of incubation. Secondly, we utilized another motility assay based on the Transwell™system, which is able to measure the cell migratory potential through nylon membrane pores. As shown in Figure 7C , in presence of 10 µM MMF WI-26 fibroblasts exhibited a much lower capacity to migrate through the Transwell™ membrane than in absence of MMF. These data, in full compliance with those obtained using the in vitro wound closure assay, allow us to conclude that MMF alter fibroblast motility.
Discussion
In this study, we unveil direct inhibitory activity of the immunosuppressive drugs MMF on several fibroblast functions that are exacerbated during fibrotic processes. Specifically, we show that MMF transcriptionally inhibits type I collagen expression, enhanced the expression of MMP-1, and alters both the migratory and contractile functions of fibroblasts. These results suggest that MMF may have direct anti-fibrotic properties in addition to its well-defined immunosuppressive effects.
MMF is a potent suppressor of T and B cell proliferation, but may also be cytostatic for monocytes, vascular smooth muscle cells and fibroblasts (Gregory et al., 1993; Allison and Eugui, 2000) . It should be noted that under our experimental conditions, (e.g., at confluency in medium containing 1% FCS), fibroblasts are contact-inhibited and do not proliferate, and MMF has no cytotoxic effect while exerting significant downregulation of collagen gene expression and contraction. Most importantly, the MMF concentrations used for this in vitro study were calculated in order to achieve similar concentrations as those currently recommended for plasma levels in clinical practice among patients treated by MMF. The daily dose recommended for these patients is 2 g orally in order to reach plasma levels varying form 1 mg/l (trough levels) to 5 mg/l at 3 hours which corresponded to concentrations of 0.1 to 10 µM (Manzia et al., 2005) .
During wound healing, fibroblasts undergo a transition to the myofibroblast phenotype, that corresponds to the commencement of connective-tissue compaction and the contraction of the wound (Singer and Clark, 1999; Desmouliere et al., 2005) . Such phenotype is also found in pathological fibrotic situations, as they occur for example during complications of organ transplantation, when excessive matrix deposition and excessive scaring takes place within the graft, leading to organ failure (Uitto and Kouba, 2000) .
In our study, MMF was shown to reduce fibroblast capacity to contract free-floating collagen lattices, accompanied with a reduction in α-SMA expression. These results are in accordance with a previous report showing that MMF reduce α-SMA production by fibroblasts in nephrectomized rats, thus preventing fibrosis (Badid et al., 2000) . α-SMA participates importantly in force JPET#117051 13 production by myofibroblasts both in vitro (Hinz et al., 2001a) and in vivo (Hinz et al., 2001b) , contributing to scar formation, tissue contraction, scar hypertrophy, and potentially, fibrosis.
Furthermore, myofibroblasts not only promote ECM contraction but also synthesize elevated levels of ECM components (Desmouliere et al., 2005) . Thus, the persistence of myofibroblasts within a fibrotic lesion leads to excessive scarring with the functional impairment of the affected organ(s).
The ability of MMF to decrease α-SMA expression and subsequent matrix contraction by fibroblast is thus likely to confer direct anti-fibrotic activities to this immunosuppressive drug. Recently, we demonstrated that rapamycin, an other immunosuppressive drug, post-transcriptionally alters fibrillar collagen synthesis by repressing their mRNA stability (Poulalhon et al., 2006) , therefore utilizing mechanisms that are clearly distinct from those of MMF. Also, rapamycin did not affect the migratory potential of fibroblast or their capacity to contract unloaded collagen lattices (unpublished data). Thus, our studies suggest that both immunosuppressive drugs directly affect fibroblast functions, but with distinct molecular mechanisms that are independent from their imunossuppressive activity.
In conclusion, we have identified MMF as a molecule that may affect fibroblast functions important for wound healing and implicated in tissue scaring and fibrosis. These results suggest that MMF represents a novel therapeutic option for the treatment of fibrotic complications of autoimmune diseases and graft rejection. 
Legends for Figures
